Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 3Unknown 2Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Alpelisib × Clear all
NCT02298595 2017-11-13

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

University of Pittsburgh

Phase 1/2 Withdrawn
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡